

# DALVANCE CONNECTS<sup>®</sup> COPAY ASSISTANCE PROGRAM



**Real-time  
benefit verification**



**Billing and  
coding support**



**Claim appeal  
support**

## INDICATION AND USAGE

DALVANCE<sup>®</sup> (dalbavancin) for injection is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-susceptible and methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus anginosus* group (including *S. anginosus*, *S. intermedius*, *S. constellatus*) and *Enterococcus faecalis* (vancomycin-susceptible isolates).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.


## IMPORTANT SAFETY INFORMATION

### Contraindications

DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.

**Please see additional Important Safety Information throughout. Please see full Prescribing Information or visit [https://www.rxabbvie.com/pdf/dalvance\\_pi.pdf](https://www.rxabbvie.com/pdf/dalvance_pi.pdf)**

**Dalvance<sup>®</sup>**   
(dalbavancin) for injection  
500 mg



# The Dalvance Connects® Copay Assistance Program



The Dalvance Connects® Copay Assistance Program may assist eligible patients with their out-of-pocket costs for DALVANCE®, up to a maximum benefit of \$2000 per calendar year.

\*Defined as at least 85% of commercial patient claims.

## Activate the Copay Assistance Program

### 3 Easy Steps for Healthcare Professionals

- 1** Complete enrollment form for consenting patients and select the Copay Assistance Program check box
  - The enrollment form can be accessed at DalvanceConnects.com within the Program Tools menu
  - Dalvance Connects® will confirm patient eligibility
- 2** Fax completed enrollment form, along with the Explanation of Benefits (EOB) or Remittance Advice (RA), to 1-855-888-7206
  - If the patient is enrolled prior to claims processing, fax EOB/RA when received from the payor
  - Claims accepted up to 120 days after the DALVANCE infusion
  - Claim forms must identify DALVANCE and outline costs associated with DALVANCE only
- 3** Once claims are reviewed and approved, checks will be mailed to providers typically within 2 weeks

### Expanded eligibility†

Any patient is eligible who:

- **IS** commercially insured
- **IS** a resident of, and is treated with DALVANCE in, the US
- **IS** administered DALVANCE in an outpatient care setting‡

†This is not insurance. Subject to change or discontinuation by AbbVie at any time.

‡Includes a practice-based or freestanding infusion center, hospital outpatient department, or home infusion service.

Please see additional Important Safety Information throughout. Please see full Prescribing Information or visit [https://www.rxabbvie.com/pdf/dalvance\\_pi.pdf](https://www.rxabbvie.com/pdf/dalvance_pi.pdf)

**Dalvance**®   
(dalbavancin) for injection  
500 mg



Most patients\*  
pay as little as

\$0



To enroll and  
activate,  
call  
1-855-387-2824,  
Option 4,  
or visit  
DalvanceConnects.com

\*Defined as at least 85% of commercial patient claims.

## IMPORTANT SAFETY INFORMATION (continued)

### Warnings and Precautions

#### Hypersensitivity Reactions

Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.

#### Infusion-related Reactions

Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, rash, and/or back pain.

#### Hepatic Effects

ALT elevations with DALVANCE treatment were reported in clinical trials.

#### *Clostridioides difficile*-associated Diarrhea

*Clostridioides difficile*-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

#### Development of Drug-resistant Bacteria

Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

#### Adverse Reactions

The most common adverse reactions in adult patients treated with DALVANCE in Phase 2/3 trials were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). The most common adverse reaction that occurred in more than 1% of pediatric patients was pyrexia (1.2%).

#### Use in Specific Populations

- There are no adequate and well-controlled studies with DALVANCE use in pregnant or nursing women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DALVANCE and any adverse effects on the breast-fed child from DALVANCE or from the underlying maternal condition.
- In patients with renal impairment whose known creatinine clearance (CLcr) is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended regimen of DALVANCE is 1125 mg, administered as a single dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis. There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years of age with CLcr less than 30 mL/min/1.73m<sup>2</sup>.
- Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients.

Please see additional Important Safety Information throughout. Please see full Prescribing Information or visit [https://www.rxabbvie.com/pdf/dalvance\\_pi.pdf](https://www.rxabbvie.com/pdf/dalvance_pi.pdf)

© 2023 AbbVie. All rights reserved.  
US-DAV-230068 09/23

DALVANCE® and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.  
Dalvance Connects® is a registered service mark of Allergan Pharmaceuticals International Limited, an AbbVie company.

**Dalvance**®   
(dalbavancin) for injection  
500 mg

abbvie

